A traditional Chinese medicine composition for treating ventricular premature beat and application thereof

Abstract

The application discloses a traditional Chinese medicine composition for treating ventricular premature beat and application thereof, and relates to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from the following raw medicinal materials in parts by weight: cassia twig 10-30 parts, prepared licorice 5-20 parts, calcined dragon bone 20-50 parts, calcined concha mali 20-50 parts, cassia bark 5-20 parts, salvia miltiorrhiza 10-30 parts, chuanxiong 10-30 parts, bupleurum 5-20 parts, white peony root 5-20 parts, bitter orange 2-20 parts, kuh-seng 10-30 parts, morindae 5-20 parts and taxilli 10-30 parts. The traditional Chinese medicine composition has the effects of invigorating heart yang, removing blood stasis and dredging collaterals, and nourishing heart and calming palpitation, can effectively treat ventricular premature beat, and has great social value for widening the current treatment method of frequent ventricular premature beat and promoting the vigorous development of the cause of traditional Chinese medicine.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating premature ventricular contractions and application thereof. BACKGROUND

[0002] Premature ventricular contractions (PVCs), also known as premature ventricular beats, are premature contractions caused by ectopic pacemakers under His bundle and its branches. Epidemiological studies show that the incidence of premature ventricular contractions is about 1% to 4%, and the incidence detected by 24-hour dynamic electrocardiogram is more than 40%, and the incidence significantly increases with age. The clinical manifestations of premature ventricular contractions are different according to the different sympathetic nervous excitability of patients, such as palpitations, heartbeat pause, and pharyngeal foreign body sensation, which mostly occur during the day when the sympathetic nervous excitability is high. Most patients can also have no obvious symptoms, but patients with occasional premature ventricular contractions can have more obvious clinical symptoms. When frequent premature ventricular contractions occur, it can cause a decrease in cardiac output, and when the blood perfusion of important organs is insufficient, it can cause chest tightness, dizziness, fatigue, syncope, and other symptoms, which seriously affect the quality of life of patients.

[0003] Modern medicine believes that the mechanism of premature ventricular contractions is the increase in the automaticity of ectopic pacemaker ventricular muscle, premature or late depolarization triggering premature contractions, and any factor that can cause premature depolarization of ventricular muscle cells is the cause of premature ventricular contractions, including structural heart disease (coronary atherosclerotic heart disease, cardiomyopathy, heart valve disease), electrolyte imbalance (hypokalemia, hypomagnesemia), drug poisoning (digitalis drugs, quinidine, tricyclic antidepressant drug poisoning) are common causes of premature ventricular contractions, and various unhealthy habits, such as excessive alcohol, coffee, tea beverage intake, smoking, mental stress, and overwork, can also induce premature ventricular contractions.

[0004] At present, the treatment of frequent premature ventricular contractions in clinical practice is mainly divided into drug treatment and surgical treatment. The drug treatment scheme mainly includes beta blockers and antiarrhythmic drugs represented by non-dihydropyridine calcium channel blockers. Although oral western medicine treatment is the most common treatment scheme for treating frequent premature ventricular contractions at present, beta blockers and non-dihydropyridine calcium channel blockers have negative inotropic and negative conduction effects, which can further slow down the heart rate, reduce the myocardial contractility, induce slow arrhythmia, and improve the clinical symptoms with different individual physical differences of patients, and long-term use is easy to cause drug resistance and obvious side effects. Patients with poor western medicine treatment effect or western medicine treatment contraindications often choose catheter radiofrequency ablation surgery treatment, but the technology belongs to invasive operation, and the treatment cost is expensive, and there are many postoperative complications. Although it is a safe, feasible and effective treatment method, the acceptance of patients is still quite limited. The traditional Chinese medicine compound can treat from multiple ion channels and multiple targets, treat patients with different physical conditions, and the clinical symptoms are improved obviously, and the side effects are small, the curative effect is lasting, and the patient compliance is high. Based on the above factors, how to provide a safe and effective traditional Chinese medicine composition for treating premature ventricular contractions is of great significance for widening the current treatment method of frequent premature ventricular contractions and promoting the vigorous development of traditional Chinese medicine industry. SUMMARY

[0005] The purpose of the present application is to provide a traditional Chinese medicine composition for treating premature ventricular contractions and its application, in order to solve the problems existing in the prior art. The traditional Chinese medicine composition provided by the present application has the effect of treating frequent premature ventricular contractions.

[0006] To achieve the above-mentioned purpose, the present application provides the following scheme:

[0007] The present application provides a traditional Chinese medicine composition for treating premature ventricular contractions, which is made of the following raw medicinal materials by weight: cassia twig 10-30 parts, fried licorice 5-20 parts, calcined dragon bone 20-50 parts, calcined concha mali 20-50 parts, cinnamon 5-20 parts, salvia miltiorrhiza 10-30 parts, chuanxiong 10-30 parts, bupleurum 5-20 parts, white peony root 5-20 parts, bitter orange 2-20 parts, kuh-seng 10-30 parts, and taxillus 10-30 parts.

[0008] Further, the traditional Chinese medicine composition is made of the following raw medicinal materials by weight: cassia twig 10-20 parts, fried licorice 5-15 parts, calcined dragon bone 20-30 parts, calcined concha mali 20-30 parts, cinnamon 10-20 parts, salvia miltiorrhiza 10-20 parts, chuanxiong 10-20 parts, bupleurum 5-15 parts, white peony root 5-15 parts, bitter orange 5-15 parts, kuh-seng 10-20 parts, and taxillus 10-20 parts.

[0009] Further, the traditional Chinese medicine composition is made of the following raw materials by weight: 15 parts of cassia twig, 10 parts of fried licorice, 25 parts of calcined dragon bone, 25 parts of calcined concha murex, 15 parts of cassia bark, 15 parts of salvia miltiorrhiza, 15 parts of chuanxiong rhizome, 10 parts of bupleurum, 10 parts of white peony root, 10 parts of immature bitter orange, 15 parts of kuh-seng, 10 parts of morindae, and 15 parts of taxilli herba.

[0010] Further, the traditional Chinese medicine composition further comprises a pharmaceutically acceptable carrier.

[0011] The "pharmaceutically acceptable" component of the present application is a component suitable for human and / or animal and without excessive adverse side effects (e.g., toxicity, irritation, etc.), i.e., a substance that has a reasonable benefit / risk ratio.

[0012] The "pharmaceutically acceptable carrier" of the present application refers to a carrier for administration of a therapeutic agent, including various excipients, diluents, etc. The carrier itself does not necessarily have relevant drug activity, but has no excessive toxicity after use. The specific carrier is well known to those skilled in the art. The specific form can be liquid or solid. The carrier can have certain auxiliary functions, such as emulsifiers, fillers, binders, disintegrants, colorants, and solubilizers, etc.

[0013] Further, the dosage form of the traditional Chinese medicine composition is an oral dosage form.

[0014] Further, the oral dosage form is a decoction.

[0015] The present application also provides the use of the above-mentioned traditional Chinese medicine composition in the preparation of a medicine for treating ventricular premature contraction.

[0016] Further, the treatment of ventricular premature contraction includes reducing the number of ventricular premature contraction episodes, reducing the 24h ventricular premature contraction load, and improving the symptoms of clinical palpitation and cardiac arrest.

[0017] Further, the medicine for treating ventricular premature contraction includes a Chinese patent medicine prepared solely from the traditional Chinese medicine composition, or a Chinese and western medicine compound preparation prepared by adding a chemical medicine for clinically treating arrhythmia.

[0018] The present application discloses the following technical effects:

[0019] The traditional Chinese medicine composition of the present application is composed of 13 common traditional Chinese medicines, i.e. Ramulus cinnamomi, Radix glycyrrhizae praeparata, Oyster shell calcined, Oyster shell calcined, Cortex cinnamomi, Radix salviae miltiorrhizae, Rhizoma chuanxiong, Radix bupleuri, Radix paeoniae alba, Fructus aurantii, Radix sophorae flavescentis, Radix glycyrrhizae praeparata and Taxilli herba. The applied medicines belong to the heart meridian and have pungent, sweet and neutral properties. According to traditional Chinese medicine, the heart belongs to fire and is the yang of yang, which governs blood vessels. When the heart yang is sufficient, the blood flows smoothly, the spirit is at ease and the heart rhythm is regular. When the elderly are long sick, or use cold and cool food and medicine, the heart yang is insufficient, which makes it difficult to continuously promote the blood flow, so the blood flow is slow, the blood vessels are not smooth, the heart rate is fast or slow, and symptoms such as palpitation, premature ventricular contraction, chest tightness and shortness of breath come with it. The traditional Chinese medicine composition is in accordance with the principle of monarch, minister, assistant and guide. The monarch is Guizhigancaolonggumugotang in Treatise on Febrile Diseases, which is combined with Ramulus cinnamomi and Radix glycyrrhizae praeparata to supplement the heart yang, and Oyster shell calcined and Oyster shell calcined to astringe and prevent the loss of nutrient QI. The minister is Sini San in Synopsis of Prescriptions of the Golden Chamber, which is combined with Radix bupleuri, Radix paeoniae alba, Fructus aurantii and Radix glycyrrhizae praeparata to circulate the three Jiaos, the nutrient QI and the defensive QI, so that the blood and the QI flow, and the QI helps the blood. The assistant is Cortex cinnamomi and Taxilli herba, which warm and invigorate the kidney yang, so that the heart and the kidney are in harmony. The four medicines, i.e. Radix sophorae flavescentis, Radix salviae miltiorrhizae, Rhizoma chuanxiong and Radix paeoniae alba, are guides, which promote the blood circulation and remove blood stasis, strengthen the function of promoting blood circulation and removing blood stasis, prevent the blood stasis and the obstruction of the heart yang.

[0020] The traditional Chinese medicine composition provided by the present application has the advantages of attacking and tonifying, convergence in dispersion, and treating the symptoms and the root cause at the same time. The composition is strict and appropriate, and takes into account the advantages of driving away evil without damaging the normal and tonifying deficiency without leaving evil. The composition fully embodies the advantages of multi-dimensional and multi-target treatment of traditional Chinese medicine, which can not only effectively improve the clinical symptoms of patients with frequent premature ventricular contractions, but also effectively reduce the number of premature ventricular contractions, reduce the 24h premature ventricular contraction load, improve the symptoms of palpitation, heart palpitation and heart stop, improve the quality of life of patients, and has significant clinical curative effect without obvious toxic and side effects and adverse reactions. The composition not only solves the clinical problems, but also widens the current treatment method for frequent premature ventricular contractions, promotes the vigorous development of traditional Chinese medicine industry, and has great social value. DETAILED DESCRIPTION

[0021] The detailed description of the various exemplary embodiments of the present application should not be considered as limiting the present application, but should be understood as a more detailed description of certain aspects, characteristics and embodiments of the present application.

[0022] It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the present application. In addition, where a range of values is provided, it is understood that each intervening value, to the upper and lower limit of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed. The upper and lower limits of these smaller ranges can independently be included or excluded in the range, and are also encompassed by the application, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included.

[0023] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. Although preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present application. All documents mentioned herein are incorporated by reference to disclose and describe the methods and / or materials in connection with which the documents are cited. In case of conflict between the present specification and any document incorporated by reference, the present specification will control.

[0024] Various modifications and changes can be made to the specific embodiments of the present application described herein without departing from the scope or spirit of the application. Other embodiments of the application will be apparent to those of ordinary skill in the art from the description and examples presented herein. The description and examples are illustrative only.

[0025] As used herein, the terms "comprises", "comprising", "includes", "including", "has", "having", "contains", "containing", or variations thereof, are intended to be open-ended terms that mean including, but not limited to.

[0026] In the following examples, the preparation method of the dosage form of the traditional Chinese medicine composition, the decoction is to wash the weighed raw materials, and boil with water. The volume ratio of total raw materials to water is 1:1.5. The decoction is boiled for 2 times, and each time for 1 hour. The liquid obtained by boiling for 2 times is combined.

[0027] Example 1

[0028] This example provides a decoction traditional Chinese medicine prepared from the following weight parts of traditional Chinese medicine composition:

[0029] Cassia bark 15 parts, fried licorice 10 parts, calcined dragon bone 25 parts, calcined concha mali 25 parts, cassia 15 parts, salvia 15 parts, chuanxiong 15 parts, bupleurum 10 parts, white peony root 10 parts, bitter orange 10 parts, sweet wormwood 15 parts, mace 10 parts, taxillus 15 parts.

[0030] Example 2

[0031] This example provides a decoction traditional Chinese medicine prepared from the following weight parts of traditional Chinese medicine composition:

[0032] Cassia twig 30 parts, fried licorice 20 parts, calcined dragon bone 50 parts, calcined concha mali 50 parts, cassia 20 parts, salvia 30 parts, chuanqiong 30 parts, bupleurum 20 parts, white peony root 20 parts, bitter orange 20 parts, sweet wormwood 30 parts, mace 20 parts, taxillus 30 parts.

[0033] Example 3

[0034] The present embodiment provides a decoction traditional Chinese medicine prepared from the following weight parts of traditional Chinese medicine composition:

[0035] Cassia twig 10 parts, fried licorice 5 parts, calcined dragon bone 20 parts, calcined concha mali 20 parts, cassia 5 parts, salvia 10 parts, chuanqiong 10 parts, bupleurum 5 parts, white peony root 5 parts, bitter orange 2 parts, sweet wormwood 10 parts, mace 5 parts, taxillus 10 parts.

[0036] Comparative Example 1

[0037] The present comparative example provides a decoction traditional Chinese medicine prepared from the following weight parts of traditional Chinese medicine composition:

[0038] Cassia twig 35 parts, fried licorice 25 parts, calcined dragon bone 15 parts, calcined concha mali 15 parts, cassia 25 parts, salvia 35 parts, chuanqiong 23 parts, bupleurum 4 parts, white peony root 4 parts, bitter orange 23 parts, sweet wormwood 8 parts, mace 25 parts, taxillus 35 parts.

[0039] Comparative Example 2

[0040] The present comparative example provides a decoction traditional Chinese medicine prepared from the following weight parts of traditional Chinese medicine composition:

[0041] Cassia twig 25 parts, calcined dragon bone 25 parts, calcined concha mali 25 parts, cassia 15 parts, salvia 15 parts, bupleurum 35 parts, white peony root 10 parts, bitter orange 10 parts, sweet wormwood 15 parts, mace 10 parts, taxillus 15 parts.

[0042] Effect verification of traditional Chinese medicine in each treatment group:

[0043] According to the clinical case observation, the number of 24-hour ventricular premature contraction occurrences and the TCM clinical symptom score were used to verify the clinical efficacy of the finished products of examples 1-3 and comparative examples 1-2 of the present application in treating frequent ventricular premature contraction.

[0044] I. Materials and methods

[0045] 1. General information

[0046] The research objects were selected from 180 cases of frequent ventricular premature contraction diagnosed and treated in the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine from July 2020 to July 2023, which met the inclusion and exclusion criteria.

[0047] 2. Diagnostic criteria

[0048] Western medicine diagnostic criteria: refer to the ninth edition of "Internal Medicine" textbook edited by Ge Junbo et al., "Expert consensus on ventricular arrhythmia" published by Chinese Medical Association about "premature ventricular contraction" related diagnostic criteria.

[0049] ①Symptoms: single premature ventricular contraction may be asymptomatic, or occasionally palpitation, chest tightness, cardiac arrest, frequent premature ventricular contraction can cause cardiac output and blood perfusion of important organs, leading to dizziness, fatigue, sweating and even the onset of angina pectoris.

[0050] ②Signs: auscultation, premature heart sounds can be heard, followed by a long period of intermittent, premature ventricular contraction of the second heart sound intensity decreased or disappeared, the first heart sound enhanced, sometimes only the first heart sound can be heard; pulse missing phenomenon can be found when palpating radial artery.

[0051] ③Electrocardiogram: premature appearance of wide QRS-T wave, QRS wave duration is usually > 0.12 s, T wave and QRS main wave direction is opposite, there is no related P wave, and there is a complete compensatory pause after it.

[0052] TCM diagnostic criteria: refer to the "Cardiopalmus" diagnostic criteria in "Internal Medicine" and "Internal Medicine Common Disease Diagnosis and Treatment Guide" published by China Medical Publishing House in 2021.

[0053] 3. Inclusion criteria:

[0054] ①Meet the western medicine diagnostic criteria of premature ventricular contraction, 24-hour dynamic electrocardiogram premature ventricular contraction number ≥2000 times; ②Meet the TCM cardiopalmus diagnostic criteria; ③The patient is 18 years old or older and less than 85 years old; ④The patient has stopped taking related cardiovascular disease Chinese medicine preparations for more than two weeks, and western medicine for more than 5 half-lives to clear the cycle; ⑤Voluntarily sign the informed consent form, can insist on taking medicine, and have good compliance.

[0055] 4. Exclusion criteria:

[0056] ①Do not meet the western medicine diagnostic criteria and TCM diagnostic criteria at the same time; ②Frequent premature ventricular contraction is more serious, accompanied by frequent ventricular tachycardia, and needs radiofrequency ablation surgery treatment; ③Patients who have undergone PCI or CABG surgery within the past 6 months, or have multiple coronary artery disease or single coronary artery stenosis greater than 70%; ④Patients with acute myocardial infarction, acute heart failure, other systemic diseases (such as anemia, hyperthyroidism, etc.), digitalis poisoning, electrolyte imbalance leading to frequent premature ventricular contraction, or ejection fraction < 45%; ⑤Patients with heart rate < 60 times / min, blood pressure < 100 / 70 mmHg, or patients with atrioventricular block and sick sinus syndrome; ⑥Patients with severe heart, liver, kidney, hematopoietic system diseases or malignant tumors that seriously affect life; ⑦Pregnant or lactating women, patients with mental illness; ⑧Patients allergic to known drug ingredients.

[0057] 5. Termination criteria

[0058] ① Abnormalities in safety indicators such as liver function, kidney function, and blood clotting function during treatment; ② Acute diseases such as acute myocardial infarction, severe arrhythmia, and cardiogenic shock during treatment; ③ Special physiological conditions or accidents during the study; ④ Occurrence of endpoint events such as patient death.

[0059] 6. Study methods

[0060] 6.1 Treatment method

[0061] 180 cases meeting the inclusion criteria were randomly divided into A, B, C, D, E, and F groups, a total of six groups, with 30 cases in each group. The general data of the 6 groups of cases were comparable (P>0.05).

[0062] Group A: Oral administration of the traditional Chinese medicine composition decoction prepared in Example 1, with a dosage of 100 ml each time, once a day in the morning, noon, and evening, taken 30 minutes after meals, with an 8-week course of treatment.

[0063] Group B: Oral administration of the traditional Chinese medicine composition decoction prepared in Example 2, with a dosage of 100 ml each time, once a day in the morning, noon, and evening, taken 30 minutes after meals, with an 8-week course of treatment.

[0064] Group C: Oral administration of the traditional Chinese medicine composition decoction prepared in Example 3, with a dosage of 100 ml each time, once a day in the morning, noon, and evening, taken 30 minutes after meals, with an 8-week course of treatment.

[0065] Group D: Oral administration of the traditional Chinese medicine composition decoction prepared in Comparative Example 1, with a dosage of 100 ml each time, once a day in the morning, noon, and evening, taken 30 minutes after meals, with an 8-week course of treatment.

[0066] Group E: Oral administration of the traditional Chinese medicine composition decoction prepared in Comparative Example 2, with a dosage of 100 ml each time, once a day in the morning, noon, and evening, taken 30 minutes after meals, with an 8-week course of treatment.

[0067] Group F: Oral administration of Bisoprolol Fumarate Tablets (manufactured by Beijing Hua Su Pharmaceutical Co., Ltd.; specification: 5 mg; batch number: GMP H20023132), 5 mg once a day, with an 8-week course of treatment.

[0068] During treatment, blood pressure and heart rate were monitored. During treatment, other anti-arrhythmic Western medicines, Chinese patent medicines, and traditional Chinese medicine products were prohibited from being taken orally. Stimulating beverages such as strong wine, coffee, and strong tea were avoided. Spicy, greasy, and cold foods were avoided. Intense exercise was avoided. Those with other underlying diseases continued to take conventional Western medicine treatment.

[0069] 6.2 Observation indicators

[0070] ①24h dynamic electrocardiogram ventricular premature number and ventricular premature ratio: ② life quality index score (SF-12).

[0071] 6.3 Safety evaluation

[0072] After 8 weeks of treatment, the patient's liver, kidney, blood coagulation function, blood, urine, stool routine were detected.

[0073] 6.4 Statistical methods

[0074] SPSS 26.0 statistical software was used for data analysis. Measurement data was expressed as "mean ± standard deviation" , paired t test was used for comparison before and after treatment within the group, independent sample t test was used for comparison before and after treatment between groups; rank sum test was used for comparison of rank data; chi-square test was used for count data, P<0.05 was considered statistically significant, P<0.01 was considered significantly different.

[0075] II. Research results

[0076] During the study, 1 case in group A, 1 case in group B, 2 cases in group C, 1 case in group D, 1 case in group E, and 2 cases in group F were dropped out.

[0077] (1) 24-hour dynamic electrocardiogram ventricular premature number and ventricular premature ratio

[0078] After treatment, the 24-hour dynamic electrocardiogram ventricular premature number and ventricular premature ratio of the 6 groups were improved (P<0.05), among which group A improved more obviously (P<0.01), as shown in Table 1.

[0079] Table 1 Comparison of 24-hour dynamic electrocardiogram ventricular premature number and ventricular premature ratio before and after treatment

[0080]

[0081]

[0082] Note: Compared with before treatment * P<0.05, compared with before treatment # P<0.01.

[0083] (2) Life quality index score improvement

[0084] The quality of life index score of the patients in group A increased from 45.66±3.01 to 50.31±2.26; the quality of life index score of the patients in group B increased from 42.77±2.80 to 48.70±1.35; the quality of life index score of the patients in group C increased from 42.51±1.65 to 47.37±1.28; the quality of life index score of the patients in group D increased from 41.36±2.03 to 45.14±2.33; the quality of life index score of the patients in group E increased from 43.51±2.26 to 45.75±2.03; and the quality of life index score of the patients in group F increased from 44.93±2.33 to 46.76±2.09.

[0085] The quality of life index score of the patients in group A increased from 45.66±3.01 to 50.31±2.26; the quality of life index score of the patients in group B increased from 42.77±2.80 to 48.70±1.35; the quality of life index score of the patients in group C increased from 42.51±1.65 to 47.37±1.28; the quality of life index score of the patients in group D increased from 41.36±2.03 to 45.14±2.33; the quality of life index score of the patients in group E increased from 43.51±2.26 to 45.75±2.03; and the quality of life index score of the patients in group F increased from 44.93±2.33 to 46.76±2.09.

[0086] Table 2: Improvement of quality of life index score

[0087] Group Example Before treatment After treatment Group A 29 45.66±3.01 50.31 ± 2.26 * ]] Group B 29 42.77±2.80 48.70 ± 1.35 * ]] Group C 28 42.51±1.65 47.37 ± 1.28 * ]] Group D 29 41.36±2.03 45.14 ± 2.33 * ]] Group E 29 43.51±2.26 45.75 ± 2.03 * ]] Group F 28 44.93±2.33 46.76 ± 2.09 * ]]

[0088] Note: compared with before treatment * P<0.05.

[0089] III. Safety evaluation

[0090] No adverse reactions were observed in the patients in each group during the 8-week medication period, and no abnormalities were observed in blood, urine, stool routine, liver and kidney functions.

[0091] The above-described embodiments are only used to describe the preferred modes of the present application, and do not limit the scope of the present application. Without departing from the design spirit of the present application, various modifications and improvements of the technical solutions of the present application made by those skilled in the art shall fall within the protection scope of the present application defined by the claims.

Claims

1. A traditional Chinese medicine composition for treating premature ventricular contractions, characterized in that, The traditional Chinese medicine composition is made from the following raw materials in parts by weight: 10-30 parts of cinnamon twig, 5-20 parts of prepared licorice root, 20-50 parts of calcined dragon bone, 20-50 parts of calcined oyster shell, 5-20 parts of cinnamon bark, 10-30 parts of salvia miltiorrhiza, 10-30 parts of chuanxiong rhizome, 5-20 parts of bupleurum root, 5-20 parts of white peony root, 2-20 parts of immature bitter orange peel, 10-30 parts of sophora flavescens root, 5-20 parts of nardostachys chinensis root, and 10-30 parts of mulberry mistletoe.

2. The traditional Chinese medicine composition according to claim 1, characterized in that, The traditional Chinese medicine composition is made from the following raw materials in parts by weight: 10-20 parts of cinnamon twig, 5-15 parts of prepared licorice root, 20-30 parts of calcined dragon bone, 20-30 parts of calcined oyster shell, 10-20 parts of cinnamon bark, 10-20 parts of salvia miltiorrhiza, 10-20 parts of chuanxiong rhizome, 5-15 parts of bupleurum root, 5-15 parts of white peony root, 5-15 parts of immature bitter orange peel, 10-20 parts of sophora flavescens root, 5-15 parts of nardostachys chinensis root, and 10-20 parts of mulberry mistletoe.

3. The traditional Chinese medicine composition according to claim 1, characterized in that, The traditional Chinese medicine composition is made from the following raw materials in parts by weight: 15 parts cinnamon twig, 10 parts prepared licorice root, 25 parts calcined dragon bone, 25 parts calcined oyster shell, 15 parts cinnamon bark, 15 parts salvia miltiorrhiza, 15 parts chuanxiong rhizome, 10 parts bupleurum root, 10 parts white peony root, 10 parts immature bitter orange peel, 15 parts sophora flavescens root, 10 parts nardostachys chinensis root, and 15 parts mulberry mistletoe.

4. The traditional Chinese medicine composition according to any one of claims 1-3, characterized in that, The traditional Chinese medicine composition also includes a pharmaceutically acceptable carrier.

5. The traditional Chinese medicine composition according to any one of claims 1-3, characterized in that, The dosage form of the traditional Chinese medicine composition is an oral dosage form.

6. The traditional Chinese medicine composition according to claim 5, characterized in that, The oral dosage form is a decoction.

7. The use of the traditional Chinese medicine composition according to any one of claims 1-6 in the preparation of a drug for treating ventricular premature contractions.

8. The application according to claim 7, characterized in that, The treatment for premature ventricular contractions includes reducing the frequency of premature ventricular contraction episodes, reducing the 24-hour premature ventricular contraction load, and improving clinical symptoms of palpitations and cardiac arrest.

9. The application according to claim 7, characterized in that, The drugs for treating premature ventricular contractions include traditional Chinese medicine preparations made solely from the aforementioned Chinese herbal composition, or compound preparations of traditional Chinese and Western medicine prepared by adding chemical drugs commonly used in the clinical treatment of arrhythmias.

Images